Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akynzeo or Olanzapine for Breakthrough CINV
NCT06065722Phase 2Recruiting
- Sponsor
- Simon Williamson Clinic
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Simon Williamson Clinic. Primary endpoint: Complete Response at 5 days. Started Sep 2023; status: recruiting.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06065722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065722.